In a statement, Fidelidade announced that the transaction is expected to be completed by the end of 2025, noting that it is “subject to the fulfillment of the usual conditions for this type of operation, namely obtaining the necessary regulatory approvals.”
The insurer emphasized that the deal with Macquarie Asset Management, through the Macquarie European Infrastructure Fund 7, values Luz Saúde at over 1.1 billion euros.
Fidelidade assured that it “will maintain a majority position in Luz Saúde, thus ensuring the continuity of the strategy in the health sector and the retention of the current management team.”
Upon completion of the transaction, the management of Luz Saúde will commence a new mandate “to further develop the company,” the insurer stated.
In May, financial information agency Bloomberg reported that Macquarie and Pure Health were among the groups that had submitted non-binding offers for a stake in Luz Saúde.
Fidelidade (85% owned by the Chinese group Fosun and 15% by Caixa Geral de Depósitos) holds almost the entirety of Luz Saúde and intends to sell 40% of the capital.
Luz Saúde owns over 30 healthcare units in Portugal, including the Hospital da Luz.
International media indicate that the Macquarie group originates from Australia and operates in 30 markets.
In 2024, Fidelidade suspended the plan to list a part of Luz Saúde on the stock exchange, citing “market instability” and the lack of conditions for “proper valuation” as reasons.
